Nick. you, Thank
the represents expanded The quarter following our in the of quarter first MACI with market. sales launch Carticel XX the second representatives not with full quarter of the in force third
convert five especially implants for not since second at engaged quarter quarter earlier increase third is base the over period years. the since change customer Carticel to previous mentioned rate surgeon call, long-term launch. consecutive user higher The expansion in and our growth conversion following a a two very strong the As demand segment and for biopsies rates interest of not never MACI of third launch, XXXX. XXXX since to who the XXXX growth MACI continues XX% in by biopsies of the used surgeons MACI. the segment. the leading near-term of third rapid the both have surgeon of quarter we In MACI far who significant surgeons revenue in full surgeon in newly our biopsies last former MACI growth, Biopsies seen the of increased had biopsies which implants and indicator first MACI in used and seen the consistent MACI MACI’s years in prospects rate have Carticel compared most two in XX% revenue been for in these MACI we quarter quarters has are very representing segment Carticel growth and expand important MACI encouraging the Overall, over and for in year-to-date from launch XX% material had the to respectively increased and the particularly Carticel from last same
programs While growth remain implant given we constant on and growth medical date appropriate the both certain Peer coming of priority. have we conversion continue the we to be XXXX. that a non-Carticel user feature biopsies, education; very marketing utilization, will been to activities former and surgical education the user volume with will in surgeons with trained MACI’s approximately are drive segments. XXX the confident Carticel procedure to over growth active this and be this to surgeons cannot trained rates XX% we that help from in accelerate continue To into ensure peer have
programs since web-based local have have case at MACI. will quarter, the wide and over be presence symposium since MACI in will also We launching strong XX both we conducted be conducting two attending presentations study QX. additional include we fourth meetings programs national, meetings and And industry in national regional, surgical national demonstrations, had launching or we MACI’s additional three will here MACI and MACI’s that training
access MACI our out access, continues schedule. on aggressive play patient to payor to Turning
a the to designed that launch updated is XX to top with policies and majority allow access able have XX was basis. following the There here strategy not now medical months of that nine we with medical Our there commercialized of MACI. report case-by-case pleased XX% a always we small equivalent will MACI We this on Carticel. which of have policies plans the estimate are to to have or but and gain for payor I’m be very which approvals over the to do these specific had coverage plan represents policies, generally the
are to of facility significant foreseeable for to Carticel positioned to in convert with anticipated a portion the are increased We volume a clean current capital room our track the without and MACI growth MACI investment we on well expand in future. capacity demand handle manufacturing
other segments. expand previous XX regions. response momentum are launch particularly it’s to policy interest, we region is of in payor access areas to expanded for geographies, a some representatives five force versus representatives sales patient the surgeon In direct support a XX MACI the the the in and to the the four announce to result expansion expansion engaged from pleased Given access medical and direct increase Carticel surgeon in newly improved need
Revenue new significant be increase QX the in the summary, as the We to by exciting plan momentum and in number same to quarter Epicel. of the the In to start Epicel this MACI now new institutions and XX% orders in representatives turn period to our ordering third saw XXXX. up of and place trained in continues progressing for according expect $X.X build of million, XXXX. sales is to quarter the over I’ll compared we product. launch third XXXX, was
should and biopsies average inherently treating expect and is are continue we the volatile, Epicel volumes that Burn Epicel of to steadily number taking centers volume grow. increasing on patients While
discussed, Epicel we training which a investment to have Epicel’s and to were in of of surgeons is result to that who our the As patient. optimal trained recent identify product. the the intended use surgeons the previously previously reengaging related and growth, phase believe Epicel standard We first had the used in growth peer on help peer Epicel of establish care
meetings, Educational take programs with held our promotional Burn and we focusing this the rates we presence lifesaving just of have will Association national at second Along Symposia improved half targeted survival dozen of half benefits more to conferences alone. efforts, powerful on Burn to our major the potential are a exhibited graft and increased and messaging and important presented – We regional than patient speaker our have reinforce Epicel. programs over at conferences and including year
burn a billing for Epicel. created be for coding hospitals with reimbursement have hotline, also severe to important we with therapy can patients. an lifesaving Finally, and aid reimbursement staffed Epicel experts
call investments will our Nick need. confident through I'll utilization, more are We support, our with reach we expanded are to that turn continued back we pleased and the its patients now. to-date and in
